-
公开(公告)号：WO2011084168A1
公开(公告)日：2011-07-14
申请号：PCT/US2010/031625
申请日：2010-04-19
Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , CHEN, Yong , HUANG, Suxian
Inventor： CHEN, Yong , HUANG, Suxian
IPC: C12Q1/68
CPC classification number: C12Q1/6818 , C12Q1/6844 , Y10T436/14 , Y10T436/142222 , Y10T436/143333 , C12Q2565/1025 , C12Q2537/143 , C12Q2531/125
Abstract: Polymeric sequence probes and methods are described that enhance the speed and sensitivity of detection of target analytes by combining a multiplicity of binding moieties specific for analyte, at least two of which are linearly arranged and optionally a multiplicity of detectable labels.
Abstract translation: 描述了聚合物序列探针和方法，其通过组合对分析物特异性的多个结合部分来增强靶分析物的检测速度和灵敏度，其中至少两个结合部分是线性排列的，并且任选地具有多个可检测标记。
-
公开(公告)号：WO2010111664A1
公开(公告)日：2010-09-30
申请号：PCT/US2010/028931
申请日：2010-03-26
Applicant: INSTITUTE FOR SYSTEMS BIOLOGY , RANISH, Jeff , LUO, Jie
Inventor： RANISH, Jeff , LUO, Jie
IPC: C08F20/00
CPC classification number: G01N33/6848 , G01N33/6845
Abstract: The invention provides improved crosslinkers which permit more efficient determination of protein interactions in biological samples.
Abstract translation: 本发明提供改进的交联剂，其允许更有效地测定生物样品中的蛋白质相互作用。
-
公开(公告)号：WO2008101214A3
公开(公告)日：2008-08-21
申请号：PCT/US2008/054168
申请日：2008-02-15
Applicant: CELATOR PHARMACEUTICALS, INC. , LOUIE, Arthur , SWENSON, Christine , MAYER, Lawrence , JANOFF, Andrew
Inventor： LOUIE, Arthur , SWENSON, Christine , MAYER, Lawrence , JANOFF, Andrew
Abstract: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.
-
公开(公告)号：WO2008008858A3
公开(公告)日：2008-01-17
申请号：PCT/US2007/073293
申请日：2007-07-11
Applicant: TRELLIS BIOSCIENCE, INC. , KADVAR, Lawrence, M.
Inventor： KADVAR, Lawrence, M.
IPC: G01N33/53 , G01N33/543 , G01N33/558 , G01N33/577
Abstract: A multiplicity of applications of the CellSpot TM assay method are described. Among these applications are extension to integral membrane protein probes, extension to secretion from bacterial cells, identification of antibodies with enhanced affinity, identification of clones with increased secretion levels, and use of massively parallel screening to identify rare efficacious antibodies.
-
公开(公告)号：WO2007115115A3
公开(公告)日：2007-10-11
申请号：PCT/US2007/065533
申请日：2007-03-29
Applicant: KEREOS, INC. , LANZA, Gregory, M. , WICKLINE, Samuel, A. , KIEFER, Garry, E. , ATHEY, Phillip, S.
Inventor： LANZA, Gregory, M. , WICKLINE, Samuel, A. , KIEFER, Garry, E. , ATHEY, Phillip, S.
IPC: A61B5/055
Abstract: MRI contrast agents that employ paramagnetic agents and chemical exchange saturation transfer (paraCEST) and which are coupled to targeted particulate delivery vehicles provide sufficient concentration of the paraCEST contrast agents to obtain useful images of target tissues or organs. In addition, the image contrast may be switched on or off with a presaturation radio frequency pulse, avoiding the necessity obtaining pre-injection and post-injection images.
-
Patent Agency Ranking
公开(公告)号：WO2020068979A1
公开(公告)日：2020-04-02
申请号：PCT/US2019/052952
申请日：2019-09-25
Applicant: CELATOR PHARMACEUTICALS, INC. , CHEUNG, Ronald , FADERL, Stefan
Inventor： CHEUNG, Ronald , FADERL, Stefan , WANG, Qi
IPC: A61K31/704 , A61K31/7068 , A61K9/127 , A61K39/395 , A61P35/02
Abstract: The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.
-
公开(公告)号：WO2019140271A3
公开(公告)日：2019-07-18
申请号：PCT/US2019/013314
申请日：2019-01-11
Applicant: PROLYNX LLC
Inventor： SANTI, Daniel V. , FONTAINE, Shaun
IPC: A61K31/70 , A61K31/44 , A61K31/335 , A61K31/50 , C08F8/00
Abstract: Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects.
-
公开(公告)号：WO2019140271A2
公开(公告)日：2019-07-18
申请号：PCT/US2019/013314
申请日：2019-01-11
Applicant: PROLYNX LLC
Inventor： SANTI, Daniel V. , FONTAINE, Shaun
IPC: A61K47/60
Abstract: Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects.
-
19.发明申请
公开(公告)号：WO2019140266A1
公开(公告)日：2019-07-18
申请号：PCT/US2019/013306
申请日：2019-01-11
Applicant: PROLYNX LLC , HEARN, Brian
Inventor： HEARN, Brian , SANTI, Daniel V. , FONTAINE, Shaun , ASHLEY, Gary W.
Abstract: Advantage is taken of the enhanced permeability and retention effect (EPR effect) to shield normal tissue from exposure to combinations of chemotherapeutic agents. Imaging agents that exhibit the enhanced permeability and retention (EPR) effect in solid tumors are useful in mimicking the behavior of chemotherapeutic or other drugs for treatment of said tumor conjugated to carriers of similar size and shape to the carriers of said imaging agents.
-
公开(公告)号：WO2016025752A1
公开(公告)日：2016-02-18
申请号：PCT/US2015/045122
申请日：2015-08-13
Applicant: PROLYNX LLC
Inventor： SANTI, Daniel, V. , FONTAINE, Shaun , HEARN, Brian , ROBINSON, Louise
CPC classification number: A61K47/545 , A61K47/6889
Abstract: Reagents for preparing stabilized thioethers for in vivo administration are disclosed, along with said thioethers thus prepared.
Abstract translation: 公开了用于制备用于体内施用的稳定的硫醚的试剂以及由此制备的所述硫醚。
-
-
-
-
-
-
-
-
-
Search Results
121
records
(took 0.014 seconds)
